A follow-up study of immunotherapy-treated birch-allergic patients: Effect on the expression of chemokines in the nasal mucosa

Clinical and Experimental Allergy

Volumn 38, Issue 7, 2008, Pages 1124-1131

  Plewako, H ^a   Holmberg, K ^a   Oancea, I ^a   Gotlib, T ^b   Samolmski, B ^b   Rak, S ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Biopsies; Chemokines; Eotaxin; Follow up; RANTES; Specific immunotherapy; TARC

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; EOTAXIN; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ALLERGEN; CHEMOKINE; CHEMOKINE RECEPTOR;

ADULT; ALLERGY; ARTICLE; BIRCH; BIRCH ALLERGY; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MAST CELL; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHINOCONJUNCTIVITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ALLERGENS; BETULA; CHEMOKINES; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; NASAL MUCOSA; RECEPTORS, CHEMOKINE;

EID: 54449096147     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03005.x     Document Type: Article

References (45)

1. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts: V. Effects of 3 years of treatment. J Allergy ClinImmunol 1991; 87:955-64.
2. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33:1076-82.
3. Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo- controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:777-83.
4. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-9.
5. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon- gamma. J Allergy ClinImmunol 1996; 97:1356-65.
6. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.
7. Plewako H, Arvidsson M, Oancea I, Hasseus B, Dahlgren U, Rak S. The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy 2004; 34:1862-7.
8. Durham SR, Varney VA, Gaga M et al. Grass pollen immunother- apy decreases the number of mast cells in the skin. Clin Exp Allergy 1999; 29:1490-6.
9. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
10. Bocchino V, Bertorelli G, Bertrand CP et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002; 57:17-22.
11. Romagnani P, De Paulis A, Beltrame C et al. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 1999; 155:1195-204.
12. Kuna P, Alam R, Ruta U, Gorski P. RANTES induces nasal mucosal inflammation rich in eosinophils, basophils, and lymphocytes in vivo. Am J Respir Crit Care Med 1998; 157: 873-9.
13. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347:669-71.
14. Bonecchi R, Bianchi G, Bordignom PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129-34.
15. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. AWHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
16. Arvidsson MB, Liiwhagen O, Rak S. Effect of 2-year placebo- controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:777-83.
17. Hedlin G, Heilborn H, Lilja G et al. Long-term follow-up of patients treated with a three-year course of cat or dog immu- notherapy. J Allergy ClinImmunol 1995; 96:879-85.
18. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts: IV. Results from long-term (6-year) follow-up. Allergy 1997; 52:914-20.
19. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of presea- sonal grass pollen immunotherapy in children. Allergy 2002; 57:306-12.
20. Bentley AM, Jacobson MR, Cumberworth V et al. Immunohistol- ogy of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992; 89:877-83.
21. Plewako H, Arvidsson M, Petruson K et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110:68-71.
22. Ahlstrom-Emanuelsson CA, Greiff L, Andersson M, Persson CG, Erjefalt JS. Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure. Eur Respir J2004; 24:750-7.
23. Lozewicz S, Gomez F, Clague J, Gatland D, Davies RJ. Allergen- induced changes in the nasal mucous membrane in seasonal allergic rhinitis: effect of nedocromil sodium. J Allergy Clin Immunol 1990; 85:125-31.
24. Plewako H, Holmberg K, Oancea I, Rak S.. Increased expression of lipoxygenase enzymes during pollen season in nasal biopsies of pollen-allergic patients. Allergy 2006; 61:725-30.
25. okkens WJ, Godthelp T, Holm AF et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non- allergic controls: a biopsy study. Clin Exp Allergy 1992; 22:701-10.
26. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immu- notherapy. Clin Exp Allergy 1991; 21:115-9.
27. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit1mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73-9.
28. Terada N, Hamano N, Kim WJ et al. The kinetics of allergen- induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001; 164:575-9.
29. Minshall EM, Cameron L, Lavigne F et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell MolBiol 1997; 17:683-90.
30. Pullerits T, Linden A, Praks L, Cardell LO, Lotvall J. Upregulation of nasal mucosal eotaxin in patients with allergic rhinitis during grass pollen season: effect of a local glucocorticoid. Clin Exp Allergy 2000; 30:1469-75.
31. Gorski P, Wittczak T, Walusiak J et al. Eotaxin but not MCP-3 induces eosinophil influx into nasal fluid in allergic patients. Allergy 2002; 57:519-28.
32. Beck LA, Dalke S, Leiferman KM et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of non- allergic and allergic human subjects. J Immunol 1997; 159: 2962-72.
33. Ying S, Robinson DS, Meng Q et al. C-C chemokines in allergen- induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163:3976-84.
34. Rajakulasingam K, Hamid Q, O'Brien F et al. RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am J Respir Crit Care Med 1997; 155:696-703.
35. Hijnen D, De Bruin-Weller M, Ossting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clinlmmunol 2004; 113:334-40.
36. Leung TF, Wong CK, Lam CW et al. Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children. Eur Respir J 2003; 21:616-20.
37. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol 2002; 110:404-9.
38. Hoshino M, Nakagawa T, Sano Y, Hirai K. Effect of inhaled corticosteroid on an immunoreactive thymus and activation- regulated chemokine expression in the bronchial biopsies from asthmatics. Allergy2005; 60:317-22.
39. Terada N, Nomura T, Kim WJ et al. Expression ofC-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clin Exp Allergy 2001; 31:1923-31.
40. Campbell JJ, Haraldsen G, Pan J et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400:776-80.
41. Nouri-Aria KT, Wilson D, Francis JN et al. CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 2002; 32:1933-8.
42. Jahnz-Rozyk K, Targowski T, Glodzinska-Wyszogrodzka E, Plusa T. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediatedal-lergicrhinoconjunctivitis.Allergy 2003; 58:595-601.
43. Akoum H, Duez C, Vorng H et al. Early modifications of chemokine production and mRNA expression during rush venom immunotherapy. Cytokine 1998; 10:706-12.
44. Hsieh KH, Chou CC, Chiang BL. Immunotherapy suppresses the production of monocyte chemotactic and activating factor and augments the production of IL-8 in children with asthma. J Allergy ClinImmunol 1996; 98:580-7.
45. Francis JN, Lloyd CM, Sabroe I, Durham SR, Tills T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy. Allergy2007; 62:59-65.